Jaw (Masseter) and Calf Muscle Hypertrophy: Causes, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Muscle hypertrophy in aesthetic medicine most commonly involves two distinct conditions: masseter muscle hypertrophy (MMH), causing squaring or widening of the lower face, and gastrocnemius-dominant calf muscle hypertrophy, causing disproportionate lower leg bulk. Masseter hypertrophy refers to bilateral or unilateral enlargement of the masseter muscle — the primary jaw-closing muscle — resulting in a widened, square mandibular angle appearance that may conflict with the V-line facial aesthetic preferred in many Asian cultures. Calf muscle hypertrophy refers to excess bulk in the medial or lateral heads of the gastrocnemius muscle, causing disproportionately large calves relative to body frame. Both conditions are benign but cause significant cosmetic distress, clothing fit difficulties, and, in the case of masseter hypertrophy, potential functional symptoms including temporomandibular joint (TMJ) pain, headache, and tooth wear from bruxism. Botulinum toxin A (BTX-A) injection is the primary and most widely used treatment for both, inducing targeted muscular atrophy through neuromuscular blockade.

Masseter hypertrophy is classified as primary (idiopathic, possibly hereditary with some familial clustering) or secondary (caused by parafunctional activity). Bruxism — involuntary, rhythmic grinding or clenching of teeth, occurring predominantly during sleep — is the most common cause of secondary masseter hypertrophy, inducing muscle work hypertrophy through repeated high-force contraction cycles. Stress, anxiety, caffeine, and stimulant use exacerbate sleep bruxism. Anabolic steroid use, temporomandibular joint disorders, and malocclusion are associated secondary causes. Calf hypertrophy is largely genetic and constitutional — determined by fiber-type composition (high proportion of type I slow-twitch fibers), muscle belly length, and insertional anatomy. Occupational or sporting activities requiring prolonged calf loading (standing, ballet, cycling, running) may worsen congenital hypertrophy. Acromegaly, Becker muscular dystrophy (pseudohypertrophy), and hypothyroidism are rare medical causes of pathological calf enlargement that must be excluded.

Masseter hypertrophy presents as bilateral (more common) or unilateral widening of the lower face with a prominent mandibular angle. The enlarged masseter is palpable as a firm, bulging mass at the jaw angle, most prominent during jaw clenching. Functional symptoms — present in 30–50% of patients — include jaw pain and fatigue after prolonged chewing, temporomandibular joint clicking or crepitus, ear pain, bruxism-related headaches (temporal headache on waking), and tooth wear (attrition). Unilateral hypertrophy may cause facial asymmetry. Calf muscle hypertrophy presents as disproportionately enlarged lower legs that persist despite low-calorie diet and are not amenable to exercise modification. Symptom burden is primarily cosmetic: difficulty fitting into knee-high boots and tapered trousers, self-consciousness in swimwear and shorts, and social avoidance. True calf hypertrophy is firm and fully reducible on dorsiflexion — distinguishing it from lipedema (non-pitting soft tissue swelling) or lymphedema.

Masseter hypertrophy is primarily a clinical diagnosis. Physical examination with bimanual palpation and measurement of masseter bulk at jaw angle in rest and clenching positions confirms the diagnosis. Panoramic dental X-ray (OPG) assesses dental wear from bruxism and identifies mandibular cortical changes. CT or MRI of the jaw (axial and coronal views) precisely measures masseter thickness and volume — important for surgical planning and BTX dose calculation. Electromyography (EMG) of the masseter demonstrates hyperactivity in bruxism. For calf hypertrophy, clinical examination is usually sufficient; MRI can delineate the contribution of gastrocnemius vs soleus vs lipomatous tissue. Ultrasound muscle thickness measurement provides real-time assessment and guides injection. Creatine kinase (CK), thyroid function tests, and neurological assessment are performed if pathological causes (myopathy, hypothyroidism) are suspected. Genetic counselling is offered for familial masseter hypertrophy with strong family history.

Botulinum toxin A (BTX-A) injection is the first-line treatment for both masseter and calf hypertrophy. For masseter hypertrophy: 25–50 units of OnabotulinumtoxinA (Botox) or 60–100 units of AbobotulinumtoxinA (Dysport) per side are injected into the masseter at 3–5 injection points per muscle under EMG or ultrasound guidance. Effects become apparent at 4–8 weeks; optimal reduction in masseter volume (15–25% reduction on MRI) occurs at 3–4 months. Treatment requires repeat sessions every 4–6 months initially, with intervals lengthening as muscles undergo permanent fibrous atrophy with repeated cycles. Dental night guards are prescribed concurrently to protect teeth from bruxism. For calf hypertrophy: 50–200 units of OnabotulinumtoxinA per gastrocnemius head are injected at multiple points; reduction in calf circumference of 1–4 cm is typically achieved. Surgical options include partial myectomy (open or endoscopic resection of medial gastrocnemius head) for refractory or severe cases — providing permanent reduction but with risk of weakness, hematoma, and nerve injury. Calf liposuction addresses concomitant subcutaneous fat but does not reduce muscle bulk.

Both masseter and calf muscle hypertrophy are benign conditions with an excellent prognosis after treatment. Botulinum toxin A injection achieves a 15–25% reduction in masseter volume on MRI after 3–4 months, with patient satisfaction rates exceeding 85% in aesthetic series. The effect is dose-dependent and reversible — repeated treatment every 4–6 months initially is required to achieve progressive and lasting muscular atrophy. After 2–3 treatment cycles, many patients experience sustained results with longer intervals between retreatments (9–12 months), as fibrous replacement of muscle tissue reduces rebound hypertrophy. For calf hypertrophy, BTX-A injection reduces calf circumference by 1–4 cm, with effects lasting 4–6 months per cycle; repeated treatment maintains the reduction. Surgical partial myectomy provides permanent volume reduction for both conditions but carries risks of hematoma, nerve injury, and muscle weakness that must be weighed against the cosmetic benefit. Bruxism-associated masseter hypertrophy does not affect oral function or health long-term if dental occlusal protection (night guard) is used concurrently and bruxism triggers are managed. Neither condition poses an oncological risk or affects life expectancy. Untreated constitutional calf hypertrophy is stable and does not progress to systemic disease. Long-term monitoring focuses on maintaining treatment gains and managing underlying bruxism or other contributing conditions.

Secondary masseter hypertrophy from bruxism can be partially prevented by managing the underlying bruxism triggers: stress reduction techniques, cognitive behavioral therapy, and avoidance of caffeine and stimulants before bedtime. Dental splints (occlusal night guards) protect teeth but do not prevent masseter hypertrophy. Early initiation of BTX-A in patients with bruxism-driven hypertrophy may prevent progressive enlargement by reducing habitual muscle overactivity. Constitutional calf hypertrophy is not preventable; avoiding intensive calf-loading exercises (isolated calf raises, jumping sports) may limit further hypertrophy in predisposed individuals. Pathological causes of muscle hypertrophy should be diagnosed and treated: thyroid hormone replacement for hypothyroidism, treatment of acromegaly — preventing irreversible structural changes.

Seek immediate evaluation for any unilateral jaw or calf swelling that is rapidly growing, firm, non-tender, and fixed — features that may suggest a soft-tissue sarcoma requiring urgent biopsy. Sudden jaw pain with restricted opening and deviation on wide opening requires TMJ evaluation by an oral and maxillofacial surgeon. Jaw hypertrophy with dysphagia, trismus, or facial nerve palsy requires urgent imaging. For calf hypertrophy, consult a neurologist if new muscle weakness, myalgia, or elevated CK accompanies the hypertrophy — these features suggest myopathy, inflammatory muscle disease, or Becker muscular dystrophy. Patients with acromegaly (large jaw, large hands, prominence of brow) combined with calf or generalized muscle hypertrophy should have growth hormone and IGF-1 levels measured and be referred to endocrinology.